MITORAINBOW THERAPEUTICS, INC.

Biotech · Private

MTR1, a dinucleotide therapeutic that metabolizes to deoxycytidine and deoxythymidine nucleotides for mitochondrial DNA synthesis in TK2 deficiency.

Grants
$1.8M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency$907,760
Federal grantDepartment of Health and Human Services · Phase II · MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency$897,699
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2158ASL Analytical, Inc.—$2.4M
2159NOVAZOI THERANOSTICS——
2160PSYENCE BIOMEDICAL LTD.—$2.0M
2161MITORAINBOW THERAPEUTICS, INC.——
2162Avanti Biosciences Inc——
2163VAXCYTE, INC.——
2164Arctus Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Treating Mitochondrial Dna Depletion Disordersapplication
  • Treating Mitochondrial Dna Depletion Disordersapplication
  • Treating Mitochondrial Dna Depletion Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.